---
title: "Ionis director Michael R. Hayden reports acquisition of 20,000 common shares worth $1,059,000"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294553943.md"
description: "Ionis Pharmaceuticals director Michael R. Hayden reported the acquisition of 20,000 common shares on behalf of his spouse, valued at approximately $1,059,000, or about $52.94 per share. Following this transaction, Hayden's indirect spouse-linked holdings increased to 24,000 shares. Additionally, he holds 54,298 Ionis common shares directly. The filing was submitted via EDGAR."
datetime: "2026-07-31T20:43:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294553943.md)
  - [en](https://longbridge.com/en/news/294553943.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294553943.md)
generator: "portal-rs"
---

# Ionis director Michael R. Hayden reports acquisition of 20,000 common shares worth $1,059,000

-   Ionis Pharmaceuticals director Michael R. Hayden reported spouse-affiliated purchases totaling 20,000 common shares at about $52.94 per share. \* Spouse-linked holdings rose to 24,000 shares held indirectly. \* Hayden reported 54,298 Ionis common shares held directly following the filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000874015-26-000254), on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [How TRYNGOLZA Approval and New Equity Shelf At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story](https://longbridge.com/en/news/295401431.md)
- [Entropy Technologies LP Makes New $2.04 Million Investment in Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/293897817.md)
- [Ionis EVP, Chief Clinical Development Officer Eugene Schneider disposes of 26,000 shares for $2.11 million](https://longbridge.com/en/news/291338585.md)
- [Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by California Public Employees Retirement System](https://longbridge.com/en/news/293717941.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**